Stock News

The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Is Gilead Sciences Stock a Buy?
Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
Travel boom poses threat to COVID-19 recovery: Doctor
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Gilead Sciences Quant Upgrade Got Me Thinking

As seen on...